Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.82
-4.7%
$0.51
$0.17
$2.93
$2.61M-0.07161,471 shs1,896 shs
Azitra, Inc. stock logo
AZTR
Azitra
$0.81
+1.5%
$1.18
$0.70
$4.44
$2.82M-1.617.98 million shs112,364 shs
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$0.01
+1.8%
$0.01
$0.00
$0.05
$696K8.9938,954 shs793 shs
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$0.97
-2.5%
$1.19
$0.85
$8.33
$3.15M0.58319,973 shs127,704 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-4.65%+11.56%+42.96%+293.85%-71.72%
Azitra, Inc. stock logo
AZTR
Azitra
+1.50%-5.44%-20.26%-53.82%-78.23%
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
+1.83%-6.72%-28.39%-34.71%-51.74%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-2.51%+6.58%-12.62%-19.84%-86.97%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
$0.82
-4.7%
$0.51
$0.17
$2.93
$2.61M-0.07161,471 shs1,896 shs
Azitra, Inc. stock logo
AZTR
Azitra
$0.81
+1.5%
$1.18
$0.70
$4.44
$2.82M-1.617.98 million shs112,364 shs
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$0.01
+1.8%
$0.01
$0.00
$0.05
$696K8.9938,954 shs793 shs
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
$0.97
-2.5%
$1.19
$0.85
$8.33
$3.15M0.58319,973 shs127,704 shs
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-4.65%+11.56%+42.96%+293.85%-71.72%
Azitra, Inc. stock logo
AZTR
Azitra
+1.50%-5.44%-20.26%-53.82%-78.23%
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
+1.83%-6.72%-28.39%-34.71%-51.74%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-2.51%+6.58%-12.62%-19.84%-86.97%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
0.00
N/AN/AN/A
Azitra, Inc. stock logo
AZTR
Azitra
0.00
N/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
0.00
N/AN/AN/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
3.00
Buy$10.00931.03% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/A$1.92 per shareN/A
Azitra, Inc. stock logo
AZTR
Azitra
$10K286.64N/AN/A$4.97 per share0.16
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
$16.65M0.04N/AN/A($0.88) per share-0.01
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/A$2.35 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
-$10.38M-$0.950.04N/AN/A-471.57%-296.50%11/12/2025 (Estimated)
Azitra, Inc. stock logo
AZTR
Azitra
-$8.97MN/A0.00N/AN/AN/A-183.57%-138.65%11/11/2025 (Estimated)
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
-$6.45M-$0.10N/AN/A-24.20%N/A-14.00%N/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-$9.57M-$38.38N/AN/AN/AN/A-341.48%-240.71%11/12/2025 (Estimated)

Latest EMMA, ENVB, AZTR, and ATXI Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/14/2025Q2 2025
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A-$0.02N/A-$0.02N/A$2.82 million
8/14/2025Q2 2025
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
-$5.25-$0.97+$4.28-$0.97N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/AN/AN/AN/AN/A
Azitra, Inc. stock logo
AZTR
Azitra
N/AN/AN/AN/AN/A
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/AN/AN/AN/AN/A
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
N/A
2.70
2.70
Azitra, Inc. stock logo
AZTR
Azitra
N/A
1.24
1.24
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
N/A
0.08
0.06
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
N/A
2.42
2.42

Institutional Ownership

CompanyInstitutional Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
17.34%
Azitra, Inc. stock logo
AZTR
Azitra
11.16%
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
7.42%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
13.82%

Insider Ownership

CompanyInsider Ownership
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
1.80%
Azitra, Inc. stock logo
AZTR
Azitra
0.25%
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
35.00%
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
1.10%
CompanyEmployeesShares OutstandingFree FloatOptionable
Avenue Therapeutics, Inc. stock logo
ATXI
Avenue Therapeutics
43.18 million2.02 millionNot Optionable
Azitra, Inc. stock logo
AZTR
Azitra
103.53 million3.52 millionNot Optionable
Emmaus Life Sciences, Inc. stock logo
EMMA
Emmaus Life Sciences
6063.87 million41.51 millionNot Optionable
Enveric Biosciences, Inc. stock logo
ENVB
Enveric Biosciences
203.25 million3.21 millionNot Optionable

Recent News About These Companies

Enveric Tanks on Successful Tests

New MarketBeat Followers Over Time

Media Sentiment Over Time

Avenue Therapeutics stock logo

Avenue Therapeutics NASDAQ:ATXI

$0.82 -0.04 (-4.65%)
As of 09/12/2025 03:44 PM Eastern

Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.

Azitra stock logo

Azitra NYSEAMERICAN:AZTR

$0.81 +0.01 (+1.50%)
Closing price 09/12/2025 04:10 PM Eastern
Extended Trading
$0.81 -0.01 (-0.62%)
As of 09/12/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Azitra, Inc., an early-stage biopharmaceutical company, develops therapies for precision dermatology using engineered proteins and live biotherapeutic products to treat skin diseases. It develops ATR-12, a genetically modified strain of S. epidermidis, which is in Phase Ib clinical trial for treating Netherton syndrome, a skin disease. The company also develops ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash experienced by cancer patients undergoing epidermal growth factor receptor inhibitor; and ATR-01, an engineered recombinant human filaggrin protein for treating ichthyosis vulgaris, a skin disease. It has a collaboration with Bayer. The company was incorporated in 2014 and is based in Branford, Connecticut.

Emmaus Life Sciences stock logo

Emmaus Life Sciences OTCMKTS:EMMA

$0.01 +0.00 (+1.83%)
As of 09/12/2025 01:13 PM Eastern

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. It has a collaboration agreement with Kainos Medicine, Inc. for the preclinical development of Kainos' patented IRAK4 inhibitor (KM10544) as an anti-cancer drug. The company was formerly known as Emmaus Holdings, Inc. and changed its name to Emmaus Life Sciences, Inc. in September 2011. The company was founded in 2000 and is headquartered in Torrance, California.

Enveric Biosciences stock logo

Enveric Biosciences NASDAQ:ENVB

$0.97 -0.03 (-2.51%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$0.99 +0.02 (+2.07%)
As of 09/12/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.